Everett Harris & Co. CA Trims Stock Position in Abbott Laboratories $ABT

Everett Harris & Co. CA reduced its stake in Abbott Laboratories (NYSE:ABT) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,467,147 shares of the healthcare product maker’s stock after selling 24,192 shares during the quarter. Abbott Laboratories comprises 2.4% of Everett Harris & Co. CA’s holdings, making the stock its 8th largest holding. Everett Harris & Co. CA owned about 0.08% of Abbott Laboratories worth $196,510,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. IMG Wealth Management Inc. grew its stake in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $29,000. Anfield Capital Management LLC increased its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at $32,000. Finally, Copia Wealth Management acquired a new position in shares of Abbott Laboratories during the 3rd quarter valued at $38,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Mizuho lifted their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Argus cut their price target on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Finally, Wells Fargo & Company upped their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $140.75.

Abbott Laboratories Stock Performance

Shares of ABT opened at $106.03 on Friday. The firm has a market capitalization of $184.36 billion, a P/E ratio of 28.50, a P/E/G ratio of 1.69 and a beta of 0.72. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $141.23. The stock has a 50 day moving average price of $123.14 and a two-hundred day moving average price of $127.64. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the business earned $1.34 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.